Last reviewed · How we verify

Centre de Recherche Médicale de Lambaréné — Portfolio Competitive Intelligence Brief

Centre de Recherche Médicale de Lambaréné pipeline: 1 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Benzimidazole Anthelmintic Benzimidazole Anthelmintic marketed

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advanz · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Centers for Disease Control and Prevention · 1 shared drug class
  4. Epicentre · 1 shared drug class
  5. Frantz Viral Therapeutics, LLC · 1 shared drug class
  6. GSK · 1 shared drug class
  7. GlaxoSmithKline · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centre de Recherche Médicale de Lambaréné:

Cite this brief

Drug Landscape (2026). Centre de Recherche Médicale de Lambaréné — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-de-recherche-m-dicale-de-lambar-n. Accessed 2026-05-16.

Related